

PTO/SB/08A		Complete if Known		RECEIVED	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/785,764 JUN 01 2001		
		Filing Date	02/16/2001 ENTER 1600/2900		
		Confirmation Number	2975		
		First Named Inventor	R. Belshe		
		Group Art Unit	1614 1648		
		Examiner Name	TBA		
Sheet	of	3	Attorney Docket No.	SLU 4538	



U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
LD	1	3,927,209	B1	Straub	12-16-1975		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
LD	2	WO	96/16672	A1	DynCorp and National Institutes of Health	06-06-1996	x
	3	WO	97/20468	A1	St. Louis University	06-12-1997	x
	4	WO	97/38138	A1	The Regents of the University of Michigan	10-16-1997	x
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
LD	5	GROSS, et al. "Persistent Infection with Parainfluenza Type 3 Virus in Man." Am. Rev. Respir. Dis, 1973, pp. 894-898, Vol. 108.					x

Examiner Signature	LD	Date Considered	6/20/01
-----------------------	----	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

MAY 29 2001

Complete if Known

RECEIVED


JUN 01 2001

TECH CENTER 1600/2900

Application Number	09/785,764
Filing Date	02-16-2001
Confirmation Number	2975
First Named Inventor	R. Belshe
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket No.	SLU 4538

Sheet 2 of 3

6	DOWNHAM et al. "Diagnosis and Clinical Significance of Parainfluenza Virus Infections in Children." Arch. Dis. Child, 1974, pp. 8-15, Vol. 49.	
7	GLEZEN, et al. "Effect of Passive Antibody on Parainfluenza Virus Type 3 Pneumonia in Hamsters." Infect. Immun., 1976, pp. 212-216, Vol. 14.	x
8	PARKINSON, et al. "Serological Evidence for Parainfluenza Virus Infection During Isolation at South Pole Station, Antarctica." Am. J. Epidemiol., 1980, pp. 334-340, Vol. 112.	
9	SARKKINEN, et al. "Type-Specific Detection of Parainfluenza Viruses by Enzyme-Immunoassay and Radioimmunoassay in Nasopharyngeal Specimens of Patients with Acute Respiratory Disease." J. Gen. Virol., 1981, pp. 49-57, Vol. 56.	
10	BELSHE, et al. "Cold Adaption of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers." J. Med. Virol., 1982, pp. 235-242, Vol. 10.	
11	WELLIVER, et al. "Role of Parainfluenza Virus-Specific IgE in Pathogenesis of Croup and Wheezing Subsequent to infection." J. Pediatr., 1982, pp. 889-896, Vol. 101.	
12	STOREY, et al. "Structural Characterization of Virion Proteins and Genomic RNA of Human Parainfluenza Virus 3." J. Virol., 1984, pp. 761-766, Vol. 52.	
13	CROOKSHANKS-NEWMAN et al., "Protection of Weanling Hamsters from Experimental Infection with Wild-Type Parainfluenza Virus Type 3 (Para 3) by Cold-Adapted Mutants of Para3." J. Med. Virol., 1986, pp. 131-137, Vol. 18.	
14	RAY, et al. "Immunochemistry of Paramyxoviruses." IN "Immunochemistry of Viruses II" (M.V.H. Van Regenmortel and A.R. Neurath, eds.), 1990, pp. 215-236, Elsevier, Amsterdam.	
15	CLEMENTS, et al. "Evaluation of Bovine, Cold-Adapted Human, and Wild-Type Human Parainfluenza Type 3 Viruses in Adult Volunteers and in Chimpanzees." J. Clin. Microbiol., 1991, pp. 1175-1182, Vol. 29.	
16	MATSOUKA, et al. "The PGene of Human Parainfluenza Virus Type 1 Encodes P and C Proteins but not a Cysteine-Rich V Protein." J. Virol., 1991, pp. 3406-3410, Vol. 65.	

Examiner Signature		Date Considered	6/20/01
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Comple ~~if known~~ **RECEIVED**

Application Number	09/785,004 1 2001
Filing Date	02-16-2001 TECH CENTER 1600/2900
Confirmation Number	2975
First Named Inventor	R. Belshe
Group Art Unit	1614 1648
Examiner Name	TBA
Attorney Docket No.	SLU 4538

Sheet 3 of 3

17	BELSHE, et al. "Evaluation of a Live Attenuated, Cold-Adapted Parainfluenza Virus Type 3 Vaccine in Children." J. Clin. Microbiol., 1992, pp. 2064-2070, Vol. 30.
18	HU, et al. "Functional Interactions Between the Fusion Protein and Hemagglutinin-neuraminidase of Human Parainfluenza Viruses." J. Virol., 1992, pp. 1528-1534, Vol. 66.
19	HALL, et al. "A Cold-Adapted Mutant of Parainfluenza Virus Type 3 is Attenuated and Protective in Chimpanzees." J. Infect. Dis., 1993, pp. 958-962, Vol. 167.
20	HENRICKSON, et al. "Epidemiology and Cost of Infection with Human Parainfluenza Virus Types 1 and 2 in Young Children." Clin. Infect. Dis., 1994, pp. 770-779, Vol. 18.
21	KARRON, et al. "A Live Human Parainfluenza Type 3 Virus Vaccine is Attenuated and Immunogenic in Healthy Infants and Children." J. Infect. Dis., 1995, pp. 1445-1450, Vol. 172.
22	COLLINS, et al. "Parainfluenza Viruses." Fields Virology, Raven Press, 1996, pp. 1205-1241, Vol. 1.

Examiner Signature		Date Considered	6/20/01
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.